Onc

Quote




































You dont stand a chance unless you have Oncology experience.
Of you get lucky to have your manager go over, you might luck out & be pulled over.
The drug is sucking since we took over.
With CEO & Pres job on the line with this buyout over paying for a company, the expansion needs aggressive & rentlentless reps who know the big writers to start moving sales or else.
Huge extreme pressure with this division on a product that is under performing.
 






You dont want to be in this 1st Oncology expansion. Trodelvi has not done anything in a year since we overpaid for it!
Yes it works well on triple negative breast cancer put patients need to be knocked out to tolerate the nasty side effects.
Oncologists will tell you most patients want off therapy after a couple doses.
As result because of side effects it is considered a dirty drug. After almost 2yrs of launch, the drug is DOA and Gilead has waited to long to expand and relaunch....
Trodelvi will be the hardest most difficult sell in Gilead's entire global portfolio bar none. As Oncologist and patients have branded a "dirty drug.
 






Yes oncology friends say Trodevly has gotten a bad brand reputation with side effects..
This is 100% Johanna fault for delaying expansion almost 2yrs while the few existing oncology reps stopped working with their new buyout 7 figures options.

DO NOT GO TO THIS DIVISION as there is a reason it has not grown since Gilead bought it
 






anonymous said:
Yes oncology friends say Trodevly has gotten a bad brand reputation with side effects..
This is 100% Johanna fault for delaying expansion almost 2yrs while the few existing oncology reps stopped working with their new buyout 7 figures options.

DO NOT GO TO THIS DIVISION as there is a reason it has not grown since Gilead bought it
Click to expand...


Then why are they hiring? Do you think it’s to ramp up for the MDS drug in phase 3?
 






























If the drug keeps poor performance the entire expanded 115 reps will be let go & sell off the division.
94% patients quit after 1st dose as can not tolerate and switch to other combo therapies instead.
Extremely dirty drug as Oncologist call it.

Johanna does not know what she is doing with the exec leadership she has hired.
A poor nasty side effect drug with a primary care mindset leader, equals worse division in Gilead to work.
As a manager who just left after the retention bonus said, "this is a dog of a drug that nobody can stay on and IG sold G actual swamp land a with a picture of Turks."

80% of the employees voluntary left including VP & ERDs & NSD last few months after 100k retention bonus was paid out.
If it was even a decent drug with good feedback and support from the Oncologists then nobody would have left let along all leadership.
 






anonymous said:
If the drug keeps poor performance the entire expanded 115 reps will be let go & sell off the division.
94% patients quit after 1st dose as can not tolerate and switch to other combo therapies instead.
Extremely dirty drug as Oncologist call it.

Johanna does not know what she is doing with the exec leadership she has hired.
A poor nasty side effect drug with a primary care mindset leader, equals worse division in Gilead to work.
As a manager who just left after the retention bonus said, "this is a dog of a drug that nobody can stay on and IG sold G actual swamp land a with a picture of Turks."

80% of the employees voluntary left including VP & ERDs & NSD last few months after 100k retention bonus was paid out.
If it was even a decent drug with good feedback and support from the Oncologists then nobody would have left let along all leadership.
Click to expand...



Terrifying if true. But if the drug is a dog, why the expansion?
 






anonymous said:
Terrifying if true. But if the drug is a dog, why the expansion?
Click to expand...

Only 30 reps from start up so need more SOV.
Also CEO has pressure to validate over paying for the buyout & jump start sales or his & Pres job are on the line!

Cant overcome side effects of sickness that keeps you bed ridden when other combo agents work with low side effects
 






anonymous said:
If the drug keeps poor performance the entire expanded 115 reps will be let go & sell off the division.
94% patients quit after 1st dose as can not tolerate and switch to other combo therapies instead.
Extremely dirty drug as Oncologist call it.

Johanna does not know what she is doing with the exec leadership she has hired.
A poor nasty side effect drug with a primary care mindset leader, equals worse division in Gilead to work.
As a manager who just left after the retention bonus said, "this is a dog of a drug that nobody can stay on and IG sold G actual swamp land a with a picture of Turks."

80% of the employees voluntary left including VP & ERDs & NSD last few months after 100k retention bonus was paid out.
If it was even a decent drug with good feedback and support from the Oncologists then nobody would have left let along all leadership.
Click to expand...
Very true
Tell tell sign is not 1 KITE Oncology employee has applied and we all know how hard a sell inner cellular agents are since Gilead bought us. But at least we dont have an agent that is so dirty with side effects that patient have to quit after 1 dose & go back to combo treatment for a quality of life.
There has been many drugs developed that worked great but make the patient miserable & they are dogs. Many of times your block buster oncology agents are the ones that work pretty good but are clean w little side effects.
Trodelvia is not one!
Flat or negative sales first couple yrs of launch is not good. 99% time ends in being a BUST.
 






Yes. Dog for sure as nobody can stay on it for even an initial starting dose

There is a reason all the big Breast cancer companies looked at this agent & decided to pass.
Merck BMS AZ Pfizer Lilly J&J all investigated and passed due to the dirty side effects & poor compliance
 












Top Bottom
Back
Quote